{"id":10323,"date":"2021-06-10T10:34:25","date_gmt":"2021-06-10T17:34:25","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=10323"},"modified":"2021-06-11T10:35:22","modified_gmt":"2021-06-11T17:35:22","slug":"neutralizing-antibodies-elicited-by-the-ad26-cov2-s-covid-19-vaccine-show-reduced-activity-against-501y-v2-b-1-351-despite-protection-against-severe-disease-by-this-variant","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/10\/neutralizing-antibodies-elicited-by-the-ad26-cov2-s-covid-19-vaccine-show-reduced-activity-against-501y-v2-b-1-351-despite-protection-against-severe-disease-by-this-variant\/","title":{"rendered":"Neutralizing Antibodies Elicited by the Ad26.COV2.S COVID-19 Vaccine Show Reduced Activity against 501Y.V2 (B.1.351) despite Protection against Severe Disease by This Variant"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> Anti-SARS-CoV-2 antibody binding responses among individuals 29 days after vaccination with the single-dose Johnson &amp; Johnson-Janssen vaccine (n=88) were reduced by 1.8-fold against the B.1.351 (Beta) variant compared to the wild-type D614G strain. By contrast, 82% in a subset of 27 individuals showed no neutralizing activity against B.1.351 (Beta) at Day 29 compared to 4% against the wild-type strain. Geometric mean neutralizing titers were also 3-fold lower against B.1.351 (Beta). The authors conclude that, given the comparable efficacy of the vaccine against the wild-type and B.1.351 (Beta) variants, these data suggest that even low levels of neutralizing antibodies may contribute to protection from moderate\/severe disease.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Moore et al.\u00a0(June 9, 2021). Neutralizing Antibodies Elicited by the Ad26.COV2.S COVID-19 Vaccine Show Reduced Activity against 501Y.V2 (B.1.351) despite Protection against Severe Disease by This Variant. Pre-print downloaded Jun 10 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.06.09.447722\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.06.09.447722<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] Anti-SARS-CoV-2 antibody binding responses among individuals 29 days after vaccination with the single-dose Johnson &amp; Johnson-Janssen vaccine (n=88) were reduced by 1.8-fold against the B.1.351 (Beta) variant compared to the wild-type D614G strain. By contrast, 82% in a subset of 27 individuals showed no neutralizing activity against B.1.351 (Beta) at Day 29&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/06\/10\/neutralizing-antibodies-elicited-by-the-ad26-cov2-s-covid-19-vaccine-show-reduced-activity-against-501y-v2-b-1-351-despite-protection-against-severe-disease-by-this-variant\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[201,142,159],"topic":[31],"class_list":["post-10323","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-immune-response","tag-vaccine","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=10323"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10323\/revisions"}],"predecessor-version":[{"id":10324,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/10323\/revisions\/10324"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=10323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=10323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=10323"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=10323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}